【恒瑞医药是哪个国家的品牌？】

江苏恒瑞医药股份有限公司始建于1970年，2000年在上海证券交易所上市，股票代码600276，是国内较大的抗肿瘤药和手术用药的研究和生产基地，目前是国内较具创新能力的大型制药企业之一。

2010年公司实现销售收入37.5亿元，利税15亿元，各项经济指标均比去年同期有大幅增长。

专注于在抗肿瘤药、手术用药、内分泌治疗药、心血管药及抗感染药等领域的创新发展，并逐步形成品牌优势。公司年生产能力达到片剂15亿片，针剂1亿支，软袋大输液1000万袋，口服液1000万瓶，胶囊1亿粒，软膏1000万支。公司所有剂型均已通过了国家GMP认证。另有4个原料药通过美国FDA认证。美国FDA官员已于2010年7月到公司进行了制剂的认证检查，为打造恒瑞医药国际性品牌凝聚辉煌。

在市场竞争的实践中，我们认识到竞争主要依赖于创新，特别是关键领域的技术创新。为此，恒瑞医药在美国、上海和连云港建有三大研究中心和一个临床医学部，拥有各类高层次专业技术人员800多名，其中有近500名博士、硕士及海归人士。

几年来，公司先后承担了4项国家863计划重大科技专项项目、9个项目列入国家“重大新药创制”专项，12项国家火炬计划项目，7项国家星火计划项目及数十项省级科技攻关项目，公司共申请了近180项发明专利，其中60项全球专利（PCT专利），有1个创新药艾瑞昔布已获批上市，另有8个创新药处于不同的临床阶段，多个创新药正申请临床。

为了在激烈的市场竞争中取得主动权，公司建立并完善了遍及全国的销售网络系统，拥有一支3000多人的销售队伍。拥有十几个年销售额过亿元以及5亿元以上的品牌产品。公司还积极拓展美国、欧洲、印度、南美等国家和地区的市场，扩大出口渠道。

英文翻译：Jiangsu Hengrui Pharmaceutical Co., Ltd. was founded in 1970 and listed on the Shanghai Stock Exchange in 2000 with the stock code of 600276. It is a large research and production base of anti-tumor drugs and surgical drugs in China. At present, it is one of the large pharmaceutical enterprises with relatively innovative ability in China. In 2010, the company achieved sales revenue of 3.75 billion yuan, profits and taxes of 1.5 billion yuan, with a substantial increase in various economic indicators over the same period last year. Focus on the innovation and development of anti-tumor drugs, surgical drugs, endocrine drugs, cardiovascular drugs and anti infective drugs, and gradually form brand advantages. The annual production capacity of the company has reached 1.5 billion tablets, 100 million injections, 10 million soft bag infusion bags, 10 million bottles of oral liquid, 100 million capsules and 10 million ointments. All dosage forms of the company have passed the national GMP certification. Another 4 APIs have passed the FDA certification. FDA officials from the United States have come to the company in July 2010 to conduct the certification and inspection of preparations, which is a brilliant way to build the international brand of Hengrui medicine. In the practice of market competition, we realize that competition mainly depends on innovation, especially in key fields. To this end, Hengrui pharmaceutical has established three research centers and a clinical medicine department in the United States, Shanghai and Lianyungang, with more than 800 high-level professional and technical personnel, including nearly 500 doctors, masters and returnees. In recent years, the company has undertaken 4 National 863 plan major science and technology projects, 9 projects listed in the national "major new drug creation" project, 12 national Torch Plan projects, 7 national Spark plan projects and dozens of provincial science and technology projects. The company has applied for nearly 180 invention patents, 60 of which are global patents (PCT patents), and 1 innovative drug irexib has Approved for marketing, another 8 innovative drugs are in different clinical stages, and multiple innovative drugs are applying for clinical application. In order to take the initiative in the fierce market competition, the company has established and improved the nationwide sales network system, with a sales team of more than 3000 people. It has more than ten brand products with annual sales of over 100 million yuan and over 500 million yuan. The company also actively expands markets in the United States, Europe, India, South America and other countries and regions, and expands export channels.

本文链接： https://www.waitui.com/brand/20042725e.html 联系电话：051881220000